At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II, Double-Blind, Randomised, Placebo-Controlled Study to Assess the Efficacy and Safety of Selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate) in Combination With Docetaxel, Compared With Placebo in Combination With Docetaxel, in Patients Receiving Second Line Treatment for Locally Advanced or Metastatic Non Small Cell Lung Cancer (Stage IIIB - IV)
In Brief
A Phase 2 clinical trial evaluating Selumetinib 75 mg, Docetaxel 75 mg/m2, and 2 other interventions for Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV. Completed, enrolled 212 participants across 68 sites in 8 countries.
Detailed Summary
The purpose of this study is to treat patients with locally advanced or metastatic NSCLC with a combination therapy of selumetinib and two different doses of docetaxel 75mg/m2 or 60 mg/m2 vs placebo and compare how well each dose affects how their cancer responds. It will also help us to understand the tolerability profile of the different dosing regimens in these patients
Study Details
Timeline
Interventions
Three selumetinib capsules (Hyd-Sulfate) 25 mg will be administered orally, twice daily, (75 mg dose bd) on an uninterrupted schedule.
Docetaxel 75 mg/m2 will be administered intravenously on day 1 of each 21 day cycle.
Docetaxel 60 mg/m2 will be administered intravenously on day 1 of each 21 day cycle.
Three placebo capsules will be administered orally uninterrupted twice daily.